Built for medical researchers, clinical scientists, biopharma professionals, healthcare investors, and regulatory professionals who need source-traced intelligence, not AI output alone. A substantial share of AI-generated clinical content can contain fabricated citations or unsupported claims. The adversarial validation infrastructure used by enterprise biopharma teams is now available to individual practitioners who cannot afford to be the ones who did not check. Start free as an Observer once your credentials are approved, then upgrade when watching the signal is no longer enough.
Four entry points. Pick the one that matches who you are. You can always switch paths later.
Physicians, researchers, clinicians, regulatory consultants, independent experts. Free Observer access after one-time approval. Upgrade for adversarial validation on the briefs you actually use.
Biopharma teams, health systems, compliance groups, enterprise buyers. Multi-user workflows. Governance, monitoring, board-ready verdicts.
Verified experts contributing review, perspective, and professional signal interpretation. Network participation, not a subscription.
Quick intake call. Three questions, one recommendation. No commitment, no sales pressure. The fastest way to land in the right room.
Every clinical decision, protocol recommendation, and formulary choice now rests on intelligence that may have been generated by AI and never adversarially validated. You probably don't know which outputs those are. That's precisely the problem.
Enterprise biopharma teams have built dedicated adversarial validation operations. Individual practitioners have been left with general-purpose AI tools that are documented to hallucinate clinical data, with no source verification and no one accountable when the output is wrong.
The gap between what AI generates and what has actually been verified is the exposure layer most practitioners are operating inside right now. It is unpriced, unmeasured, and the regulators who will eventually ask about it are not waiting for practitioners to catch up.
Not another dashboard. A source-traced signal desk for people who need to know what changed, why it matters, and whether it deserves escalation.
Why pharmacists and operators care: when a signal carries its own source chain, deciding whether it deserves escalation stops being guesswork.
This is an institutional review pathway, not a deployment you flip on. Each step is scoped through review, and the team intelligence pathway is available by enterprise conversation.
One approval, full access ladder. Observer access is free once your credentials are approved. Each paid tier includes the Decision Integrity Engine with hallucination containment and verified source chain. No long-term contracts. Cancel at any time, subject to terms.
Decision infrastructure for organizations where intelligence failure becomes financial, clinical, or regulatory exposure.
Pharmaceutical intelligence sovereignty for nations that cannot depend entirely on external visibility.
Growth, Enterprise, and Sovereign tiers are configured for multi-team intelligence operations with custom integrations, expert-validated support, and service-level terms defined during onboarding.
You may not need paid access today. That is why Observer starts free after approval. You may already have tools. AimwellBio is not here to replace every tool. It is here to help verify what deserves attention. You may simply want to see whether the intelligence layer is real. Start as an Observer.
Every listed profile is a credentialed researcher, clinician, or regulatory professional whose datasets feed the Cortex engine. Apply to join →
Dr. Christopher A. Jones, PhD, MSc, FRSM, a verified FHIN Founding Pro, is the kind of professional this network is built for. His public profile shows what verified presence in the network looks like. View his profile →
How does your team currently catch the citation that does not survive a reviewer's check?
Plus: every Signal subscriber gets the next edition of The Adversarial Validation Standard, citation-eligible. Founding members of Signal/Shield get personal onboarding with John Morgan.
Hand us anything your team is about to use. We return a source-risk review with every citation traced. No sales call. No follow-up sequence. The review itself is the conversation.
You are not afraid of the AI. You are afraid of being the person who quoted the citation that did not exist, the one your reviewer found before you did.
See Practitioner Tiers →Teams searched documents, reviewed guidance updates, followed trial movement, tracked competitors, and built internal briefs by hand. Slow but auditable. Every claim had a paper trail.
Speed. The same brief that took a week now takes minutes. The trade-off: unsupported claims, stale guidance, missing context, and incomplete summaries can now move into serious decisions before anyone challenges them.
AimwellBio is the verification layer that sits between AI-generated intelligence and the decision someone signs their name to. Source-trace, adversarial review, confidence labels, institutional memory.
Seven ways unsupported scientific intelligence can enter regulatory, clinical, board, and investor workflows. Open to credentialed professionals. No sales sequence, no list-trading.